20395-87-3

Usage

Uses

Used in Pharmaceutical Industry:
2-(Benzyloxycarbonylamino)butyric acid is used as a precursor for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its ability to serve as a building block in the creation of complex organic compounds makes it invaluable in the advancement of medicinal chemistry.
Used in Organic Chemistry Research:
In the field of organic chemistry, 2-(Benzyloxycarbonylamino)butyric acid is utilized as a protecting group in peptide synthesis. It is employed to temporarily block specific functional groups on amino acids, allowing for controlled and selective reactions to occur. This selective protection is crucial for the successful synthesis of complex peptide sequences and the development of novel bioactive molecules.
Used in Peptide Synthesis:
2-(Benzyloxycarbonylamino)butyric acid is used as a protecting group in the synthesis of peptides, ensuring that the desired sequence of amino acids is achieved without unwanted side reactions. This selective protection is essential for the successful assembly of peptides with specific biological activities and properties.
Overall, 2-(Benzyloxycarbonylamino)butyric acid plays a multifaceted role in various applications across the pharmaceutical and chemical industries, from the synthesis of complex molecules to the development of innovative drug delivery systems and therapeutic agents. Its versatility and importance in organic chemistry make it a valuable compound for researchers and chemists alike.

Upstream product

• 1492-24-6 L-2-aminobutyric acid 
• 501-53-1 benzyl chloroformate 
• 26054-60-4 ((S)-2-Oxo-oxetan-3-yl)-carbamic acid benzyl ester 
• 917-54-4 methyllithium 
• 56-84-8 L-Aspartic acid 
• 2835-81-6 2-aminobutanoic acid 
• 232598-63-9 (1-nitromethyl-propyl)-carbamic acid benzyl ester 
• 127862-66-2 2-Benzyloxycarbonylamino-butyric acid 2,2,2-trifluoro-ethyl ester 
• 97-94-9 triethyl borane 
• 40522-79-0 2-aminobutyric acid hydrochloride 
• 31139-36-3 dibenzyl dicarbonate 
• 4124-76-9 N-(benzyloxycarbonyl)-L-glutamic acid anhydride 

Downstream Products

• 132562-61-9 N-((S)-2-amino-butyryl)-L-tyrosine ethyl ester; hydrochloride 
• 92235-10-4 N-((S)-2-benzyloxycarbonylamino-butyryl)-glycine ethyl ester 
• 1170-50-9 Benzyloxycarbonyl-α-amino-butyrylglutamin 
• 2830-15-1 O--glykolsaeure-(4-nitro-benzylester) 
• 16305-77-4 N-Benzyloxycarbonyl-L-α-amino-butyryl-glycin-benzylester 
• 2747-97-9 N--glycin-<4-nitro-benzylester> 
• 117194-57-7 Z-Abu-Sar-O-(t-Bu) 
• 116823-65-5 Z-Abu-Sar-(Me)Leu-Val-(Me)Leu-Ala-D-Ala-(Me)Leu-(Me)Leu-(Me)Val-OBut 
• 22373-14-4 [(1S)-1-(hydroxymethyl)propyl]carbamic acid benzyl ester 
• 185213-14-3 N-benzyloxycarbonyl-(2S)-aminobutyryl-(2S)-indolinecarboxylic acid ethylamide 
• 185213-06-3 N-benzyloxycarbonyl-(2S)-aminobutyryl-(2S)-indolinecarboxylic acid propylamide 
• 869307-73-3 N-benzyloxycarbonyl-(2S)-aminobutyryl-(D/L)-phenylalanine ethyl ester 
• 185213-02-9 N-benzyloxycarbonyl-(2S)-aminobutyryl-(2S)-indolinecarboxylic acid n-butylamide 
• 305859-68-1 (R,S)-4-benzyloxycarbonylamino-4,5-dihydro-2(3H)-furanone 

Relevant academic research and scientific papers

Identification, characterization, synthesis and strategy for minimization of potential impurities observed in the synthesis of brivaracetam

A first systematic impurity profile research concerning nine observed and potential process related impurities of antiepileptic drug brivaracetam is reported. Among which three (impurity G/H/I) have not been discovered or reported before, these nine impurities were monitored by HPLC, and their structures were identified on the basis of MS and NMR spectroscopy. In addition to the formation, synthesis, and characterization, strategies for minimizing these impurities to the levels accepted by ICH are also described in this report.

Oxazolidin-2-one-Pyrimidine Derivatives

The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

Assay and inhibition of diacylglycerol lipase activity

A series of N-formyl-α-amino acid esters of β-lactone derivatives structurally related to tetrahydrolipstatin (THL) and O-3841 were synthesized that inhibit human and murine diacylglycerol lipase (DAGL) activities. New ether lipid reporter compounds were developed for an in vitro assay to efficiently screen inhibitors of 1,2-diacyl-sn-glycerol hydrolysis and related lipase activities using fluorescence resonance energy transfer (FRET). A standardized thin layer chromatography (TLC) radioassay of diacylglycerol lipase activity utilizing the labeled endogenous substrate [1″- 14C]1-stearoyl-2-arachidonoyl-sn-glycerol with phosphorimaging detection was used to quantify inhibition by following formation of the initial product [1″-14C]2-arachidonoylglycerol and further hydrolysis under the assay conditions to [1-14C]arachidonic acid.

Resolution of non-proteinogenic amino acids via microbial lipase-catalyzed enantioselective transesterification

A number of non-proteinogenic amino acids bearing aliphatic side chains were resolved with moderate to good enantioselectivities (E = 15-42) through the Burkholderia cepacia lipase-catalyzed enantioselective transesterification of the 2,2,2-trifluoroethyl esters of their N-benzyloxycarbonyl derivatives with methanol as a nucleophile in diisopropyl ether.

Resolution of non-protein amino acids via Carica papaya lipase-catalyzed enantioselective transesterification

Carica papaya lipase-catalyzed transesterification of the 2,2,2-trifluoroethyl esters of N-benzyloxycarbonylated dl-amino acids carrying aliphatic side chains proceeded smoothly and, in almost all the cases, enantiospecifically (E = >200), affording the l-methyl esters and leaving the d-trifluoroethyl esters intact.

Fluorescein-based metal sensors, and methods of making and using the same

The present invention is directed, in part, to fluorescein-based ligands for detection of metal ions, and methods of making and using the same.

Tripeptidylpeptidase inhibitors

A compound of formula wherein the substituents are defined as in the specification and salts or hydrates thereof is disclosed as well as a method of treating disorders associated with the inactivation or excessive degradation of cholecystokinin.

THIAZOLIDINE DERIVATIVES

An object of the present invention is to provide novel thiazolidine derivatives which are useful as drugs. The thiazolidine derivatives according to the present invention are compounds represented by the following general formula [I] and salts thereof, wherein R 1is alkyl, hydroxy, alkoxy, alkoxyalkyl, phenyl, phenylalkyl, phenylalkoxy, phenoxy, phenoxyalkyl, amino, alkylamino or a nonaromatic heterocycle; R 2is H or alkyl; R 3is H, alkyl or phenyl; R 4is H or alkyl; R 5is alkyl, halogenoalkyl, hydroxy, alkoxy, phenyl, phenylalkoxy, phenoxy, carboxyl, alkoxycarbonyl, phenylalkoxycarbonyl or an aromatic heterocycle; A 1is alkylene; and A 2is alkylene.

Solid-phase synthesis of unnatural α-amino acid derivatives using a resin-bound glycine cation equivalent

Unnatural amino acids were synthesized on solid-phase by reaction of a resin-bound Schiff base with organoboranes. This novel use of a resin-bound glycine cation equivalent allows for the preparation of a variety of amino acid structural types not readily available by the complementary anionic equivalent.

Base assisted substitution of α-amidoalkyl sulfones by nitromethane anion. A new entry to functionalized α-amino acids

The nitromethane anion reacts with α-amidoalkyl sulfones in THF affording the corresponding nitro derivatives that upon oxidation with alkaline potassium permanganate give the corresponding N-protected α-amino acids.